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Summary
 
In approximately 20% of cases of severe congenital neutropenia (SCN), mutations are found in
the gene encoding the granulocyte colony-stimulating factor receptor (G-CSF–R). These mu-
tations introduce premature stop codons, which result in truncation of 82–98 COOH-terminal
amino acids of the receptor. SCN patients who develop secondary myelodysplastic syndrome
and acute myeloid leukemia almost invariably acquired a 
 
GCSFR
 
 mutation, suggesting that
this genetic alteration represents a key step in leukemogenesis. Here we show that an equiva-
lent mutation targeted in mice (
 
gcsfr-
 
D
 
715
 
) results in the selective expansion of the G-CSF–
responsive progenitor (G-CFC) compartment in the bone marrow. In addition, in vivo treat-
ment of 
 
gcsfr-
 
D
 
715 
 
mice with G-CSF results in increased production of neutrophils leading to a
sustained neutrophilia. This hyperproliferative response to G-CSF is accompanied by pro-
longed activation of signal transducer and activator of transcription (STAT) complexes and ex-
tended cell surface expression of mutant receptors due to defective internalization. In view of
the continuous G-CSF treatment of SCN patients, these data provide insight into why progen-
itor cells expressing truncated receptors clonally expand in vivo, and why these cells may be
targets for additional genetic events leading to leukemia.
Key words: neutropenia • severe congenital neutropenia • granulocyte colony-stimulating 
factor receptor • mutations • acute myeloid leukemia
 
S
 
evere congenital neutropenia (SCN)
 
1
 
 is a heteroge-
neous hematopoietic disorder characterized by a pro-
found neutropenia due to a maturation arrest of granulo-
cytic progenitor cells in the bone marrow (BM). As a
result, SCN patients suffer from recurrent, often life-threat-
ening, bacterial infections (1). The disease presents with a
variable inheritance, and the mechanisms underlying its
pathogenesis are largely unknown (2–5). Granulocyte col-
ony-stimulating factor (G-CSF) is a major regulator of neu-
trophil production (6, 7). However, although defective
production of G-CSF has been suggested as a possible cause
of SCN in isolated cases (8, 9), in the majority of SCN pa-
tients G-CSF serum levels are normal or elevated (10–12).
In 
 
.
 
90% of SCN patients, daily administration of pharma-
cological doses of G-CSF increases neutrophil levels and
significantly reduces infection-related events (1, 13). In
contrast, treatment with GM-CSF is rarely effective (13),
suggesting that specifically the G-CSF signal transduction
pathway is affected in SCN.
G-CSF mediates its effects through activation of its cog-
nate receptor (G-CSF–R), a single-transmembrane protein
of the hematopoietin receptor superfamily which forms
homooligomeric complexes upon ligand binding (14–16).
Like all members of this group of receptors, G-CSF–R
lacks intrinsic tyrosine kinase activity but can activate cyto-
plasmic tyrosine kinases of the Jak and Src families (17–23).
These kinases tyrosine phosphorylate substrates, including
the receptor, to provide docking sites for other proteins,
which, in turn, can be phosphorylated as well. Proteins
docking to the G-CSF–R complex include members of the
signal transducer and activator of transcription (STAT)
 
1
 
Abbreviations used in this paper:
 
 AML, acute myeloid leukemia; BM, bone
marrow; CAFC, cobblestone area–forming cell; CFC, colony-forming
cell; EPO, erythropoietin; SCF, stem cell factor; SCN, severe congenital
neutropenia; STAT, signal transducer and activator of transcription. 
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family. Upon tyrosine phosphorylation, STATs form di-
meric complexes and translocate to the nucleus, where
they influence gene transcription (24, 25). Of the six
members of the STAT family identified in mammalian
cells, STAT1, STAT3, and STAT5 have been implicated
in G-CSF signaling (19, 26–29). STAT3 has recently
been linked with IL-6–induced macrophage differentiation
and G-CSF–induced neutrophilic differentiation (30–32),
whereas STAT5 has been implicated in the control of
hemopoietic cell proliferation by some cytokines, including
G-CSF (33, 34).
In a subgroup of SCN patients, acquired mutations in
the 
 
GCSFR
 
 gene are found in BM and peripheral blood
neutrophils (18, 35–39). These mutations introduce pre-
mature stop codons that result in the truncation of 82–98
COOH-terminal amino acids, a region previously impli-
cated in the control of neutrophilic differentiation (40, 41).
In recent studies of a total of 78 SCN patients, 18 cases
with point mutations in the critical region in the 
 
GCSFR
 
gene were found (38, 42). Among those patients with
 
GCSFR
 
 mutations, eight developed acute myeloid leuke-
mia (AML), whereas only one of the patients without a
mutation has thus far showed clinical or cytogenetic evi-
dence of leukemic progression (38). This latter patient rep-
resents a rare case of autosomal dominant SCN affecting a
mother and four siblings. Up to now, no 
 
GCSFR
 
 muta-
tions have been detected in patients with idiopathic neu-
tropenia, chronic myeloid leukemia (CML), or myelodys-
plastic syndrome (MDS) without history of neutropenia.
However, mutations occur at very low frequency in de
novo AML (18, 43–45). These clinical observations suggest
that acquisition of a 
 
GCSFR
 
 mutation may be a critical
step in the leukemic transformation of progenitor cells
from SCN patients.
Recently, we generated mice with a mutation in their 
 
gcsfr
 
gene (
 
D
 
715
 
) equivalent to one of the nonsense mutations
found in SCN patients (46). Both homozygous and hetero-
zygous 
 
D
 
715
 
 mice have reduced numbers of circulating
neutrophils compared with their 
 
wt/wt 
 
littermates, supporting
the notion that the G-CSF–R COOH terminus has a role in
granulopoiesis in vivo. Strikingly, after injection with G-CSF,
 
gcsfr-wt/
 
D
 
715 
 
and 
 
gcsfr-
 
D
 
715/
 
D
 
715 
 
mice showed increased
peripheral neutrophil counts compared with their 
 
wt/wt
 
 lit-
termates (46). Analysis of cells labeled with the thymidine an-
alogue 5-bromo-2
 
9
 
-deoxyuridine in vivo indicated that the
rise was due to de novo generation of neutrophils, although
specific mechanistic details were not addressed.
In this study, we show that the 
 
gcsfr-
 
D
 
715
 
 mutation re-
sults in an approximately twofold increase in granulocyte
colony-forming cell (G-CFC) content in the BM. In con-
trast, the numbers of more primitive hematopoietic pro-
genitors, as assessed in a cobblestone area–forming cell
(CAFC) assay (47), are slightly decreased. Sustained G-CSF
treatment results in a continuous neutrophilia in 
 
gcsfr-
 
D
 
715
 
 mice, suggesting a persistent increase in G-CSF–
induced proliferation of neutrophilic progenitors due to the
G-CSF–R truncation. Finally, we demonstrate altered lev-
els and kinetics of G-CSF–induced activation of STAT
proteins in 
 
gcsfr-
 
D
 
715
 
 mice, including a significantly ex-
tended activation of STAT proteins that correlated with a
delay in internalization of the truncated G-CSF–R pro-
teins. These altered signaling properties provide potential
explanations for the preleukemic nature of 
 
GCSFR
 
 muta-
tions in SCN.
 
Materials and Methods
 
Mice. gcsfr-
 
D
 
715
 
 mice (46) and control littermates were
housed in a specific pathogen–free environment. F1 and F2 mice
were generated from 
 
gcsfr-wt/
 
D
 
715 
 
(129/OLA 
 
3 
 
FVB/N) par-
ents, and mice were used at the age of 2–3 mo. The 
 
gcsfr-
 
D
 
715
 
mutation was back-crossed on an FVB/N background. Progeny
of 
 
gcsfr-wt/
 
D
 
715
 
 mice of the third back-cross generation were
used in the in vivo G-CSF treatment experiment, in two out of
four in vitro colony assays, and in one of the two CAFC assays.
 
Blood and BM Sampling.
 
Blood samples were collected from
the tail vein at fixed time points to avoid variation due to circa-
dian rhythms (48). Blood cell counts were performed on a Sys-
mex-K1000X automated counter (Toa Medical Electronics Co.
Ltd.). To obtain BM cell suspensions, femurs and tibias were
crushed in a mortar in HBSS with 5% FCS (HBSS/FCS). BM
cells were passed through a 100-
 
m
 
m sieve, spun down, and re-
suspended. The resulting monocellular suspensions contained
98–99% viable cells, as determined by trypan blue exclusion. For
differential countings, blood smears were fixed in methanol,
May-Grunwald-Giemsa (MGG) stained. At least 300 blood cells
were analyzed in a Zeiss Axioscope microscope.
 
Isolation of BM Progenitor Cells.
 
BM cells of two mice were
pooled and suspended in HBSS/FCS and subsequently incubated
in a 162-cm
 
2
 
 cell culture flask (Costar) in a humidified atmo-
sphere of 5% CO
 
2
 
 in air at 37
 
8
 
C for 1 h. Nonadherent cells were
spun down and resuspended in 45% (
 
r
 
 
 
5 
 
1.058) Percoll (Phar-
macia Fine Chemicals) solution in Ca
 
2
 
1
 
/Mg
 
2
 
1
 
-free HBSS. Cells
were then loaded on a Percoll density gradient as described (49).
BM progenitor cells were collected from the interface between
the layers with densities of 1.058 and 1.064. Cells were washed
twice in Ca
 
2
 
1
 
/Mg
 
2
 
1
 
-free HBSS supplemented with 0.2% BSA
(HBSS/BSA). The cell numbers recovered in these fractions from
 
wt/wt
 
, 
 
wt/
 
D
 
715
 
, and 
 
D
 
715
 
/
 
D
 
715
 
 mice were similar.
 
In Vitro Colony Assays.
 
BM progenitor cells were plated in
triplicate in 35-mm Petri dishes (Falcon; Becton Dickinson) con-
taining 1 ml of methylcellulose medium (Methocult M3230;
Stem-cell Technologies, Inc.) containing 30% fetal bovine serum,
1% BSA, 0.1 mM 2-ME, 2 mM 
 
l
 
-glutamine, without additional
growth factor or with 100 ng/ml G-CSF (Amgen, Inc.), 20 U/ml
murine GM-CSF (provided by Dr. Steven Neben, Genetic Insti-
tute, Cambridge, MA), 100 U/ml murine macrophage (M)-CSF,
4 U/ml human erythropoietin (EPO; a gift of Janssen-Cilag) plus
10 
 
m
 
g/ml murine stem cell factor (SCF) and 0.2 mM hemin (bo-
vine type 1; Sigma). Colonies (50 cells or more) were counted on
day 7 or 8 of culture. CAFC assays were performed as described
(47). In this limiting dilution assay, phase-dark hematopoietic colo-
nies (cobblestone areas) are formed under a preestablished stromal
layer. Early appearing cobblestone areas (week 1–2) represent
clones from the relatively mature stem/progenitor cell subset,
while the most primitive hemopoietic stem cells, i.e., those with
long-term repopulating abilities in vivo, are assessed at week 4–5.
 
Preparation of Nuclear Extracts.
 
BM cells isolated as described
above were washed once with HBSS, resuspended in RPMI/
10% FCS, and transferred to a tissue culture flask. After 1.5 h, 
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nonadherent cells were transferred to a fresh flask for another 3.5 h
before stimulation with murine IL-3 (100 ng/ml) or human
G-CSF (100 ng/ml). Stimulation was terminated by adding ice-
cold PBS containing 0.1 mM Na
 
3
 
VO
 
4
 
. Cells were lysed in 200
 
m
 
l hypotonic buffer (20 mM Hepes, 20 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
,
1 mM Na
 
4
 
P
 
2
 
O
 
7
 
, 0.125 
 
m
 
M okadaic acid, 1 mM EDTA, 1 mM
EGTA, 0.2% NP-40, 1 mM dithiothreitol, 0.5 
 
m
 
g/ml aprotinin,
0.5 
 
m
 
g/ml leupeptin, 0.5 
 
m
 
g/ml bacitracin, 0.5 
 
m
 
g/ml iodoace-
tamide, and 1 mM Pefabloc). Nuclei were spun down at 15,000 
 
g
 
for 30 s, and proteins were extracted by rocking for 30 min at 4
 
8
 
C
in 20 
 
m
 
l high-salt buffer (hypotonic buffer with 420 mM NaCl,
and 20% glycerol). Insoluble materials were removed by centrifu-
gation at 20,000 
 
g
 
 at 4
 
8
 
C for 20 min.
 
Electrophoretic Mobility Shift Assays with STAT-binding Oligonu-
cleotides.
 
Nuclear extracts were incubated with double-stranded
[
 
g
 
-P
 
32
 
]ATP end-labeled STAT1- and STAT3-binding oligonu-
cleotide m67 (5
 
9
 
-CATTTCCCGTAAATC-3
 
9
 
; reference 50) or
STAT1- and STAT5-binding oligonucleotide (5
 
9
 
-AGATTTCT-
AGGAATTCAATCC-3
 
9
 
) derived from the 5
 
9
 
 regulatory region
of the 
 
b
 
-casein gene (51). Binding reactions were performed for
30 min at room temperature in a 20-
 
m
 
l reaction volume contain-
ing 3 
 
m
 
l nuclear extract, 1 
 
m
 
l dIdC (2 mg/ml), 11 
 
m
 
l H
 
2
 
O, 4 
 
m
 
l 5
 
3
 
binding buffer (50 mM Hepes, pH 7.6–7.8, 85 mM NaCl, 15 mM
NaMoO
 
4
 
, 4.25 mM dithiothreitol, and 25% glycerol), and 1 
 
m
 
l
labeled double-stranded oligonucleotides (10.2 ng/
 
m
 
l). The re-
action mixtures were fractionated by electrophoresis on 5% poly-
acrylamide gels containing 5% glycerol in 0.25
 
3
 
 TBE (Tris-boric
acid-EDTA). In supershift experiments, 2 
 
m
 
l of either anti-STAT1,
anti-STAT3 (Santa Cruz Biotechnology), or anti-STAT5 antibod-
ies (provided by B. Groner, Institute of Experimental Cancer Re-
search, Tumor Biology Center, Freiburg, Germany) was added to
the reaction mixture and incubated for 30 min on ice, before the
addition of the radiolabeled oligonucleotides. The gels were dried
and subsequently analyzed by autoradiography. For quantitation,
gels were exposed to PhosphorImager screens and analyzed with
ImageQuant software (Molecular Dynamics).
 
Flow Cytometric Analysis of G-CSF–R Internalization.
 
G-CSF–R
expression on BM cells was measured by flow cytometry. To this
end, G-CSF was biotinylated using 
 
d
 
-biotinoyl-
 
e
 
-aminocaproic
acid-
 
N
 
-hydroxy-succinimide ester (Biotin-7-NHS; Boehringer
Mannheim). Free biotin was removed by gel filtration on Sepha-
dex G-25. BM cells (10
 
6
 
) were incubated for various times at
37
 
8
 
C with 0.2 
 
m
 
g/ml biotinylated G-CSF. Subsequently, cells
were incubated for 30 min at 4
 
8
 
C with PE-conjugated streptavi-
din (SA-PE; Caltag Labs) in the presence of 0.05% NaN
 
3
 
. Cells
Figure 1. Selective expansion of the G-CFC compartment in BM of
gcsfr-D715 mice. BM cells of two mice of each genotype were pooled,
enriched for progenitor cells, and plated in triplicate in methylcellulose-
containing media supplemented with various growth factors. Hemo-
poietic colonies containing 50 cells or more were scored after 7–8 d. Data
are mean 6 SD.
Table I. Numbers of Progenitor Cells and Primitive Stem Cells 
Estimated in the CAFC Assay
No. of CAFCs/femur
gcsfr-wt/wt gcsfr-wt/D715 gcsfr-D715/D715
Experiment 1
Week 1 78,400 75,700 116,600
2 51,400 49,300 68,300
3 30,700 24,900 24,800
4 15,300 7,970 7,330
5 3,560 2,110 2,680
Experiment 2
Week 1 59,800 67,400 75,400
2 12,200 13,900 25,700
3 7,310 9,880 10,300
4 3,640 2,070 2,370
5 1,330 650 650
BM cells of two mice (one femur per mouse) were pooled and plated
in a limiting dilution in 96-well plates on FBMD-1 stromal feeders.
CAFCs were scored on weeks 1–5. Early appearing cobblestone areas
(week 1–2) represent clones from the relatively mature stem/progenitor
cell subset, whereas the most primitive hemopoietic stem cells, i.e.,
those with long-term repopulating abilities in vivo, are assessed at week
4–5. Data of two independent experiments are given.
Figure 2. Numbers of progenitor cells and
primitive hemopoietic stem cells in gcsfr-D715
mice measured by CAFC assays. BM cells were
plated under a layer of stromal cells. Cobble-
stone areas were counted weekly and expressed
as the number of CAFCs per femur relative to the CAFC number per femur
of gcsfr-wt/wt mice. Data are mean 6 SD of two independent experiments.686 Sustained G-CSF Receptor Activation in an SCN Mouse Model
were subjected to flow cytometric analysis on a FACS®. A win-
dow was set on the basis of forward and side light scatter to re-
strict the analysis to myeloid cells.
Results
Numbers of Myeloid Progenitors Are Increased in gcsfr-D715
Mice. We have previously shown that gcsfr-D715 mice are
neutropenic (46). To determine at what stage of myeloid
development the effect of the D715 mutation becomes
phenotypically overt, we performed in vitro colony assays
in the presence of specific growth factors. Depending on
the factor(s) added, these assays provide a quantitative mea-
sure of the number of neutrophilic precursors (G-CSF),
granulocyte-macrophage precursors (GM-CSF), macro-
phage precursors (M-CSF), and erythroid precursors (EPO
plus SCF). Data from a representative experiment are
shown in Fig. 1. The frequency of G-CSF–responsive
CFCs was increased by a factor 2.0 6 0.6 (mean 6 SD of
four independent experiments) in homozygous D715 mice,
and 1.8 6 0.9 in heterozygous mice compared with wild-
type littermates. Although the frequencies of GM-CSF,
M-CSF, and EPO plus SCF responsive progenitors were also
consistently higher in mutant mice, the difference between
mutant and wild-type mice was less pronounced than that
in the granulocytic lineage.
We next evaluated the effect of the mutation on more
primitive hemopoietic cells in the CAFC assay. From the
CAFC numbers per femur of gcsfr-wt/wt, wt/D715, and
D715/D715 mice (Table I), we calculated the percentage
of CAFCs relative to the CAFC numbers of wild-type
mice (Fig. 2). Although CAFCs at week 1–2 (a measure of
stem cells with short-term repopulating ability) were rela-
tively more abundant in the gcsfr-D715/D715 mice, CAFCs
at week 4–5 (primitive stem cells with long-term repopu-
lating ability) were present in lower numbers than in con-
trol mice. Therefore, it appears that the absence of the
COOH-terminal domain of the G-CSF–R leads to a selec-
tive expansion of a myeloid progenitor compartment, to
some extent at the expense of primitive stem cells.
gcsfr-D715 Mice Develop Sustained Neutrophilia in Response
to Long-term G-CSF Treatment. Previously, we showed
Figure 3. Sustained neutrophilia in gcsfr-D715 mice induced by in vivo
G-CSF treatment. Mice were injected subcutaneously with G-CSF (250 mg/
kg/d) for 22 d. Blood was collected and analyzed as described in Materials
and Methods. Data are means 6 SD of four animals for each genotype.
Figure 4. Sustained activation of
STAT complexes by D715 G-CSF–R.
Electrophoretic mobility shift assay of
nuclear extracts prepared from BM
cells, stimulated with G-CSF or IL-3
for the indicated times. (A) Time
course of STAT1 and STAT5 activa-
tion using b-casein probe. Supershifts
with antibodies against STAT1 and
STAT5 indicated that the lower band
contained STAT1 and the upper two
bands contained STAT5 (reference
29). (B) Time course of STAT1 and
STAT3 activation using m67 probe.
Supershifts showed that the lower two bands contained STAT1, whereas the upper two bands contained STAT3 (reference 29). (C) Quantitative analysis
of time course of STAT-binding kinetics, setting STAT5 activation of wild-type receptors at 15 min to 100%.687 Hermans et al.
present on the cell surface (Fig. 6, A and B). Thus, upon
exposure to G-CSF, truncated G-CSF–Rs reside longer on
the cell surface, which may contribute to their ability to in-
duce sustained STAT activation.
Discussion
Before the therapeutic use of G-CSF for SCN patients,
incidental cases terminating in AML were reported (54).
After the introduction of G-CSF treatment of SCN pa-
tients, mortality due to severe opportunistic bacterial infec-
tions diminished, but the incidence of secondary AML
gradually increased. The frequency of leukemic progression
is currently estimated at 7.5–10% (55). After the discovery
of mutations in the gene encoding the G-CSF–R in several
SCN patients, a correlation was observed between the ac-
quisition of such mutations and leukemic progression of
the disease (37, 42). The consequences of these mutations
for the signaling function of G-CSF–R have initially been
investigated in myeloid cell lines. These studies revealed
that truncated receptors transduce strong proliferative sig-
nals, but are defective in maturation signaling (40, 41).
To gain further insight in the contribution of GCSFR
mutations to the pathogenesis of SCN and AML, we re-
that gcsfr-wt/D715 and gcsfr-D715/D715 mice injected with
G-CSF for 1 wk have elevated blood neutrophil counts on
days 6 and 7 compared with control littermates (46). To es-
tablish whether this effect is transient or sustained, gcsfr-wt/wt,
gcsfr-wt/D715, and gcsfr-D715/D715  mice were injected
daily with G-CSF (250 mg/kg) for 22 d, and blood neutro-
phil numbers were monitored. Wild-type mice responded
to G-CSF treatment with a 10-fold increase in their blood
neutrophil levels, mice heterozygous for the D715 muta-
tion with a 65-fold increase, and gcsfr-D715/D715 mice
with a 250-fold increase (Fig. 3). The average blood neu-
trophil count on day 23 was 45 3 106/ml in D715/D715
mice (n 5 4), 27 3 106/ml in wt/D715 mice, and 6 3 106/ml
in wt/wt mice. Thus, it is clear that G-CSF treatment leads
to a sustained neutrophilia in gcsfr-D715 mice. Red blood
cell and platelet counts were not influenced by the muta-
tion, suggesting that the gcsfr-D715 mutation selectively en-
hances the proliferation of myeloid progenitors.
Kinetics of G-CSF–induced Activation of STAT Complexes
in gcsfr-D715 Mice. Because there is increasing evidence
that STAT proteins play an important role in the control of
proliferation and differentiation of hematopoietic cells, we
analyzed both STAT5 and STAT3 activation in BM cells
of gcsfr-wt/wt, wt/D715, and D715/D715 mice. At early
time points (up to 15 min), G-CSF–induced activation of
STAT5 was largely unaffected while STAT3 activation was
reduced in D715/D715 BM cells (Fig. 4, A and B). How-
ever, at later time points of stimulation (60 and 120 min),
when STAT5 activation in wt/wt cells declined, activation
of STAT5 in D715/D715 cells persisted, whereas STAT3
levels became comparable in both. Quantification of the
signals (Fig. 4 C) shows that after 1–3 h of stimulation,
STAT5 activation in BM cells of D715 mice is four- to
fivefold the STAT5 activation in wild-type BM cells,
whereas STAT3 activation after 1–3 h of stimulation is
similar. BM cells from heterozygous mice showed an inter-
mediate response (data not shown). IL-3–induced activa-
tion of STAT complexes was equivalent in all genotypes.
We also studied STAT activation after 10 min of stimu-
lation followed by an extensive wash to remove G-CSF.
Under these conditions, prolonged activation of STAT5,
STAT3, and STAT1 was seen in D715/D715 cells and to a
somewhat lesser extent in wt/D715 cells (Fig. 5, A and B).
These findings suggest that the truncated receptors which
bound ligand during the first 10 min of stimulation were
responsible for the prolonged STAT activation, and that
this was not due to stimulation of new receptors recruited
to the cell surface. Because wild-type and truncated recep-
tors show equivalent Kd (41), this suggests that receptor de-
activation is altered in truncated receptors.
Ligand-mediated Internalization of Truncated G-CSF–R Is
Delayed. The COOH-terminal region of G-CSF–R con-
tains a dileucine motif (STQPLL) that has been implicated
in ligand-mediated receptor endocytosis (52, 53). Due to
the truncation, D715 G-CSF–Rs lack this motif. When ex-
posed to G-CSF, within 30 min, surface expression of
wild-type receptors had decreased to 20% of the initial ex-
pression, whereas 80% of the mutant receptors were still
Figure 5. Prolonged activation of STAT complexes in gcsfr-D715 mice
after removal of G-CSF. BM cells were stimulated with G-CSF or IL-3
for 10 min, washed extensively, and incubated in RPMI/10% FCS. Nu-
clear extracts were prepared at the indicated times and assayed as de-
scribed above using STAT1- and STAT5-binding b-casein probe (A) or
STAT1- and STAT3-binding m67 probe (B). Left and right panels repre-
sent independent experiments.688 Sustained G-CSF Receptor Activation in an SCN Mouse Model
cently generated an in vivo model by introducing an SCN-
derived nonsense mutation (gcsfr-D715) in mice (46). Both
wt/D715 and D715/D715 mice have significantly reduced
numbers of blood neutrophils compared with their wt/wt
littermates, suggesting that the G-CSF–R COOH-terminal
domain contributes to neutrophil development in vivo.
This phenotype has remained consistent and independent
of genetic background in the mice generated so far. In con-
trast, other investigators have reported that blood neutro-
phil numbers in mice with a similar mutation in the gcsfr
gene were not significantly altered (56). However, a com-
plication of their model is that the expression of the mutant
allele was significantly higher than the wild-type allele.
This might be due to the fact that the PGK-neo cassette
used for selection of embryonic stem cells within the gcsfr
gene had not been removed before the generation of ani-
mals. This increased expression of truncated G-CSF–R
may compensate for the mutation, and could explain the
absence of neutropenia.
In gcsfr-D715 mice, the numbers of CAFCs at week 5
appear slightly reduced in BM, whereas the numbers of
G-CFCs are selectively expanded. As yet, we cannot explain
this relative paucity of primitive stem cells in D715 mice.
One possibility is that expression of truncated G-CSF–Rs
on these cells would lead to an increase in cell cycling and
commitment. However, whether primitive hemopoietic
stem cells express G-CSF–R is still controversial (57, 58).
The fact that the numbers of IL-3–, M-CSF–, and GM-
CSF–responsive CFCs are also increased in gcsfr-D715 mice
suggests that the GM-CFC compartment is already some-
what expanded. Despite the increased G-CFC compart-
ment, the number of circulating neutrophils is significantly
reduced in gcsfr-D715 mice (46). This implies that truncated
receptors do impair the development to blood neutrophil,
but at what stage between the G-CFC and mature neutro-
phil this defect becomes manifest remains unclear.
The gcsfr-D715 mice showed a sustained neutrophilia in
response to G-CSF administration. The fact that this hyper-
proliferation persisted after prolonged exposure to G-CSF
is compatible with the notion that the rate of proliferation
of the early myeloid progenitor compartment is increased
in these mice. Increased proliferation due to G-CSF–R
truncation has also been observed in cell lines (40, 41).
However, immortalized cell lines contain multiple genetic
aberrations that influence cell cycle regulation. We have
shown here in primary cells that the gcsfr-D715 mutation it-
self is sufficient for an in vivo hyperproliferative response to
G-CSF. This supports the idea that acquisition of this type
of mutation represents a step in leukemic transformation.
In SCN patients, expansion of progenitor cells with ac-
quired G-CSF–R mutations is observed. Thus, it is con-
ceivable that under continuous G-CSF administration,
such as that received by SCN patients, progenitor cells that
acquire a GCSFR mutation would have a proliferative ad-
vantage leading to their in vivo expansion.
STAT proteins are involved in control of multiple cellu-
lar processes regulated by cytokines and growth factors,
including cell differentiation, proliferation, and survival.
Since the BM from gcsfr-wt/wt, gcsfr-wt/D715, and gcsfr-
D715/D715 mice appears similar in composition, also
Figure 6. Comparison of internalization kinetics of full-length and truncated
G-CSF–R. BM cells were incubated with biotinylated G-CSF at 378C for the in-
dicated periods and then stained with SA-PE. (A) Shaded histogram, t 5 0; solid
line, t 5 15 min; bold line, t 5 30 min; dotted line, t 5 4 h. (B) Peak fluorescence
standardized for t 5 0 as a function of time.689 Hermans et al.
within the neutrophilic lineage (46), we could directly
compare G-CSF–induced activation of STAT proteins in
the BM of these mice. BM cells from gcsfr-D715 mice dis-
played normal levels of STAT5, but decreased levels of
STAT3 activation. The latter is most likely due to the ab-
sence of specific STAT3-activating mechanism(s) (26, 29).
In view of the putative role of STAT3 in G-CSF–induced
differentiation of neutrophilic progenitors (32), the de-
creased STAT3 activation could, at least partially, explain
the defective maturation to blood neutrophil which leads
to basal neutropenia in gcsfr-wt/D715 and gcsfr-D715/D715
mice. Importantly, truncated G-CSF–Rs induced prolonged
activation of STAT complexes and showed slower inter-
nalization rates. However, the relative levels of G-CSF–
induced activation of STAT5 versus STAT3 in gcsfr-D715
BM were consistently higher than in gcsfr-wt BM. This may
shift the proliferation/differentiation balance within the
neutrophilic progenitor cells. There is increasing evidence
that oncogenesis is associated with abnormal STAT signal-
ing (59). For example, constitutive STAT activation has
been reported in cells transformed by Src, Abl, and other
oncoproteins (60–64). In human tumors, e.g., breast carci-
noma cells, lymphomas, and leukemias, STATs are also fre-
quently activated (63, 65–67). In view of these findings, our
observation that the kinetics of STAT activation by trun-
cated G-CSF–Rs are altered further corroborates the idea
that GCSFR mutations truncating the COOH terminus of
the receptor are a step in leukemogenesis in SCN patients.
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